Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Harrison

Showing results (101-110 of 218) with videos related to

Pageof 22
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2006
A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasisMelanie J Percy, Quan Zhao, Adrian Flores, et al.
Haematologica|September 3, 2016
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studiesVikas Gupta, Claire Harrison, Elizabeth O Hexner, et al.
Genome Research|July 10, 2021
Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasmsStephania Contreras Castillo, Bertille Montibus, Azucena Rocha, et al.
Blood Advances|July 8, 2020
Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding studyVikas Gupta, Denise Wolleschak, Hans Hasselbalch, et al.
British Journal of Haematology|March 12, 2019
UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPNClaire Harrison, Jonathan Mathias, Maz Campbell-Drew, et al.
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.
Haematologica|September 8, 2009
Identification of high oxygen affinity hemoglobin variants in the investigation of patients with erythrocytosisMelanie J Percy, Nauman N Butt, Gerard M Crotty, et al.
The Lancet. Haematology|May 16, 2022
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 studyNaveen Pemmaraju, Jacqueline S Garcia, Jalaja Potluri, et al.
Yeast (Chichester, England)|September 19, 2024
Exploring Saccharomycotina Yeast Ecology Through an Ecological Ontology FrameworkMarie-Claire Harrison, Dana A Opulente, John F Wolters, et al.
Blood Advances|August 2, 2023
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosisVikas Gupta, John Mascarenhas, Marina Kremyanskaya, et al.
Pageof 22

Showing results (101-110 of 218) with videos related to

Sort By:
Pageof 22
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2006
A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasisMelanie J Percy, Quan Zhao, Adrian Flores, et al.
Haematologica|September 3, 2016
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studiesVikas Gupta, Claire Harrison, Elizabeth O Hexner, et al.
Genome Research|July 10, 2021
Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasmsStephania Contreras Castillo, Bertille Montibus, Azucena Rocha, et al.
Blood Advances|July 8, 2020
Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding studyVikas Gupta, Denise Wolleschak, Hans Hasselbalch, et al.
British Journal of Haematology|March 12, 2019
UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPNClaire Harrison, Jonathan Mathias, Maz Campbell-Drew, et al.
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.
Haematologica|September 8, 2009
Identification of high oxygen affinity hemoglobin variants in the investigation of patients with erythrocytosisMelanie J Percy, Nauman N Butt, Gerard M Crotty, et al.
The Lancet. Haematology|May 16, 2022
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 studyNaveen Pemmaraju, Jacqueline S Garcia, Jalaja Potluri, et al.
Yeast (Chichester, England)|September 19, 2024
Exploring Saccharomycotina Yeast Ecology Through an Ecological Ontology FrameworkMarie-Claire Harrison, Dana A Opulente, John F Wolters, et al.
Blood Advances|August 2, 2023
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosisVikas Gupta, John Mascarenhas, Marina Kremyanskaya, et al.
Pageof 22